Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Revenue
Solventum Corporation's revenue for fiscal 2025 was $8.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $8.3B. Revenue has risen for 3 consecutive fiscal years. Solventum Corporation ranks 6th of 51 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $8.3B | 0.86% |
| FY2024 | $8.3B | 0.70% |
| FY2023 | $8.2B | 0.82% |
| FY2022 | $8.1B | — |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $2.2B | 10.06% |
| Mar 2026 | $2.0B | 0.45% |
| Dec 2025 | $2.0B | (4.68%) |
| Sep 2025 | $2.1B | (3.01%) |
| 10 more quarters | Free account |
Revenue against peers
| Company | Revenue |
|---|---|
| BAX Baxter International Inc. compare | $11.5B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation | $8.3B |
| AVTR Avantor, Inc. compare | $6.6B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| ALGN Align Technology, Inc. compare | $4.1B |
| ATR AptarGroup, Inc. compare | $3.9B |
| WST West Pharmaceutical Services, Inc. compare | $3.3B |
| RGEN Repligen Corporation compare | $785.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SOLV
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement